The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Abbasian Mohammad Hadi; Ansarinejad Nafiseh; ABBASI BAHAREH; IRAVANI MASOUD; RAMIM TAYEB; Hamedi Fahime; ARDEKANI ALI M.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Avicenna Journal of Medical Biotechnology Year:2020 | Volume:12 | Issue:3 Page(s): 157-164

Download Full-Text

View:

200

Download:

145

Cites:

Information Journal Paper

Title

The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population

Author(s)

Keywords

5-fluorouracil

Dihydropyrimidine dehydrogenase

Fluoropyrimidines

Pharmacogenetics

Thymidylate synthase

Abstract

Background: The fluoropyrimidine drug 5-fluorouracil (5-FU) and the prodrug capecitabine have been extensively used for treatment of many types of cancer including colorectal, gastric, head and neck. Approximately, 10 to 25% of patients suffer from severe fluoropyrimidine-induced toxicity. This may lead to dose reduction and treatment discontinuation. Pharmacogenetics research could be useful for the identification of predictive markers in chemotherapy treatment. The aim of the study was to investigate the role of five genetic polymorphisms within two genes (DPYD, TYMS) in toxicity and efficacy of fluoropyrimidine-based chemotherapy. Methods: Total genomic DNA was extracted from 83 cancer patients treated with fluoropyrimidine-based chemotherapy. In this study, three polymorphisms were genotyped in Dihydropyrimidine dehydrogenase gene c. 1905+1 G>A (DPYD*2A; rs3918290), c. 1679 T>G (I560S; DPYD*13; rs55886062), and c. 2846A>T (D949V; rs67376798) and two polymorphisms, besides the Variable Number of Tandem Repeat (VNTR) polymorphism and 6-bp insertion/deletion polymorphism in Thymidylate synthase gene. The analysis of polymorphisms for rs3918290, rs55886062, rs67376798 and 6-bp insertion/ deletion in TYMS was done by Polymerase Chain Reaction-restriction Fragment Length Polymorphism (PCRRFLP) TYMS VNTR analysis. 5-FU-related toxicities such as anemia, febrile neutropenia, neurotoxicity, vomiting, nausea, and mucositis were evaluated according to NCI-CTC criteria version 4. 0. T-test and chi-square were used and p-values less than 0. 05 were considered statistically significant. Results: DPYD gene polymorphisms were not observed in this study. The frequency of the TYMS +6 bp allele was 40. 35% and the-6 bp allele was 59. 65% in this study. The frequency of VNTR 2R allele was 48. 75% and 3R allele was 51. 15%. Toxicity grade II diarrhea, mucositis, nausea, vomiting, and neurotoxicity was 2. 2, 24. 1, 15. 7, 6, and 51. 8%, respectively. Thymidylate synthase ins/del polymorphisms were associated with increased grade III neurotoxicity (p=0. 02). Furthermore, anemia grade III was significantly associated with 2R/2R genotype (0. 009). Conclusion: Thymidylate synthase gene polymorphisms may play a key role in fluoropyrimidne-based chemotherapy. Although rare DPYD polymorphisms were not observed in our study, according to large population studies, DPYD gene polymorphisms could be used as a predictive biomarker for patient treatments.

Cites

No record.

References

Cite

APA: Copy

Abbasian, Mohammad Hadi, Ansarinejad, Nafiseh, ABBASI, BAHAREH, IRAVANI, MASOUD, RAMIM, TAYEB, Hamedi, Fahime, & ARDEKANI, ALI M.. (2020). The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population. AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), 12(3), 157-164. SID. https://sid.ir/paper/758673/en

Vancouver: Copy

Abbasian Mohammad Hadi, Ansarinejad Nafiseh, ABBASI BAHAREH, IRAVANI MASOUD, RAMIM TAYEB, Hamedi Fahime, ARDEKANI ALI M.. The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population. AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB)[Internet]. 2020;12(3):157-164. Available from: https://sid.ir/paper/758673/en

IEEE: Copy

Mohammad Hadi Abbasian, Nafiseh Ansarinejad, BAHAREH ABBASI, MASOUD IRAVANI, TAYEB RAMIM, Fahime Hamedi, and ALI M. ARDEKANI, “The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population,” AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), vol. 12, no. 3, pp. 157–164, 2020, [Online]. Available: https://sid.ir/paper/758673/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops